MCL is an aggressive B cell malignancy which is incurable with standard therapies. In this video, the current standard of care (SOC) for mantle cell lymphoma (MCL), including not only the established therapies but also the emerging therapies that will impact the management of MCL in the future,...

Treating elderly MM patients is challenging because of the heterogeneity of this patient population. This needs to be taken into consideration when choosing treatments. Full dose ASCT can be considered in patients <65 years of age. Between the ages of 65-70, reduced intensity ASCT can still...